Clinical Trials Browser

Meningeal Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Nervous System Diseases, Nervous System Neoplasms, Pathologic Processes, Central Nervous System Neoplasms, Meningeal Carcinomatosis

NCT07092202 2025-07-29

Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

Phase 4 Recruiting

40 enrolled

CNS

Meningeal Carcinomatosis

NCT06762080 2025-05-20

Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

Phase 1/2 Recruiting

36 enrolled

CNS

Meningeal Carcinomatosis

NCT06809517 2025-05-20

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

Phase 1/2 Recruiting

34 enrolled

CNS

Meningeal Carcinomatosis

NCT06809530 2025-05-18

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

Phase 1/2 Recruiting

34 enrolled

CNS

Meningeal Carcinomatosis

NCT05746754 2025-04-06

CSI ProLong

Phase NA Recruiting

50 enrolled

CNS

Meningeal Carcinomatosis

NCT06901817 2025-03-30

A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases

Phase 2 Recruiting

97 enrolled

CNS

Meningeal Carcinomatosis

NCT06643000 2025-03-06

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Phase NA Recruiting

60 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06812871 2025-02-06

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Phase 2 Recruiting

30 enrolled

CNS

Meningeal Carcinomatosis

NCT06728865 2024-12-11

Better Brain

Phase 2 Recruiting

70 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06431685 2024-05-28

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

Phase 1 Recruiting

10 enrolled

CNS

Meningeal Carcinomatosis

Clinical Trials

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Concurrent Azeliragon With Craniospinal Irradiation

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer

Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

ETIC-LM

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread

CA2024-LM-001

Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

CSI ProLong

A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Better Brain

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer